Sign In
Buy VOR
$21.15
-0.650 (-2.98%)
At Close: Jul 31, 2026
Vor Bio Appoints RA Capital's Andrew Levin, M.D., Ph.D., and Forbion's Wouter Joustra to Board of Directors
04:01pm, Tuesday, 23'rd Dec 2025
BOSTON, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Vor Biopharma Inc. (Nasdaq: VOR), a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, today announce
Vor Bio Announces $150 Million Private Placement
08:00am, Monday, 15'th Dec 2025
BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, announced today that it has entered into a se
Vor Biopharma Inc. (NASDAQ:VOR) Receives Consensus Recommendation of “Hold” from Brokerages
02:14am, Tuesday, 02'nd Dec 2025
Vor Biopharma Inc. (NASDAQ: VOR - Get Free Report) has been given a consensus rating of "Hold" by the eleven ratings firms that are presently covering the company, MarketBeat Ratings reports. One equi
Reviewing Vor Biopharma (NASDAQ:VOR) and Liminatus Pharma (NASDAQ:LIMN)
01:12am, Saturday, 29'th Nov 2025
Vor Biopharma (NASDAQ: VOR - Get Free Report) and Liminatus Pharma (NASDAQ: LIMN - Get Free Report) are both small-cap manufacturing companies, but which is the superior business? We will contrast the
Vor Biopharma (VOR) Upgraded to Buy: Here's What You Should Know
01:00pm, Tuesday, 25'th Nov 2025
Vor Biopharma (VOR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Head to Head Analysis: Liminatus Pharma (NASDAQ:LIMN) versus Vor Biopharma (NASDAQ:VOR)
05:22am, Sunday, 16'th Nov 2025
Liminatus Pharma (NASDAQ: LIMN - Get Free Report) and Vor Biopharma (NASDAQ: VOR - Get Free Report) are both small-cap manufacturing companies, but which is the better stock? We will compare the two b
Vor Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update
04:01pm, Thursday, 13'th Nov 2025
Multiple Late-Stage Data Readouts Reinforce Telitacicept's Broad Potential Across Autoimmune Diseases Expansion of Executive Leadership and Board Strengthens Global Development Capabilities
Vor Biopharma Secures $100 Million Offering After Reporting Efficacy In Kidney Disease Trial
09:43am, Tuesday, 11'th Nov 2025
Vor Biopharma Inc. (NASDAQ:VOR) on Tuesday priced an underwritten public offering of 10 million shares at $10.00 per share.
Vor Bio Announces Pricing of Public Offering of $100 Million of Common Stock
09:56pm, Monday, 10'th Nov 2025
BOSTON, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Vor Biopharma Inc. (Nasdaq: VOR), a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, today announced the p
Vor Bio Announces Proposed Public Offering of $100 Million of Common Stock
04:01pm, Monday, 10'th Nov 2025
BOSTON, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Vor Biopharma Inc. (Nasdaq: VOR) (Vor Bio), a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, today annou
Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China
11:45am, Saturday, 08'th Nov 2025
Treatment with telitacicept for 39 weeks resulted in a rapid, clinically meaningful, and statistically significant reduction in proteinuria, with a favorable safety profile
Vor Bio to Participate in Upcoming Investor Conferences
08:00am, Friday, 07'th Nov 2025
BOSTON, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will participate in t
/PRNewswire/ -- ACTO, ein führender Anbieter von KI-gestützten Spitzenlösungen für die Biowissenschaften, Veeva-Produktpartner und Mitglied des Veeva
Vor Bio Appoints Jeremy Sokolove, M.D. as Chief Medical Officer
08:00am, Monday, 03'rd Nov 2025
BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of Jeremy Sok
Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Friday, 31'st Oct 2025
BOSTON, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on October 15, 2025, th
